AstraZeneca AZN announced that the FDA has accepted the supplemental new drug application (sNDA), seeking approval for the expanded use of Calquence (acalabrutinib) in mantle cell lymphoma (MCL ...

AstraZeneca Plc's AZN supplemental New Drug Application for Tagrisso (osimertinib) in combination with chemotherapy has been accepted and granted Priority Review in the U.S. for locally advanced ...

CLL is the most common form of leukemia, with an estimated 191,000 new cases globally and 20,720 new cases in the U.S. each year, AstraZeneca has said.

Sacramento, Calif.-based Sutter Health has joined forces with biopharmaceutical company AstraZeneca to develop a research and innovation collaboration focused on personalized care for ...

The highly redacted FDA Form 483 was issued (PDF) to AstraZeneca’s ZS Pharma unit following a January inspection of its plant in Coppell, Texas.

By Najat Kantouar AstraZeneca said it and Daiichi Sankyo decided to voluntarily withdraw the marketing authorization application in the European Union for advanced lung-cancer treatment Dato-DXd ...